fibrinogen has been researched along with Coronary Restenosis in 13 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 10 (76.92) | 29.6817 |
| 2010's | 2 (15.38) | 24.3611 |
| 2020's | 1 (7.69) | 2.80 |
| Authors | Studies |
|---|---|
| Chen, T; Sun, JL; Zhang, J | 1 |
| Isobe, M; Itai, A; Muto, S; Ogawa, M; Suzuki, J; Yamaguchi, Y | 1 |
| Bryan, D; Dippel, E; Jerin, M; Rauba, J; Shammas, G; Shammas, NW | 1 |
| Arefieva, TI; Bespalova, ZhD; Chazov, EI; Gorshkov, BG; Krasnikova, TL; Ksenevich, TI; Kukhtina, NB; Nikitin, PI; Noeva, EA; Potekhina, AV; Provatorov, SI; Ruleva, NU; Sidorova, MV | 1 |
| Bellomo, G; Bongo, AS; Di Mario, C; Lazzero, M; Lupi, A; Nardi, F; Rognoni, A; Rolla, R; Rossi, L; Secco, GG | 1 |
| Hayashi, Y; Imazu, M; Kohno, N; Otsuka, M; Ueda, H | 1 |
| Jaeger, BR; Labarrere, CA | 1 |
| Agema, WR; de Maat, MP; de Winter, RJ; Doevendans, PA; Frants, RR; Jukema, JW; Kastelein, JP; Monraats, PS; Rana, JS; Tio, RA; van der Laarse, A; van der Wall, EE; Waltenberger, J; Zwinderman, AH | 1 |
| Grubitzsch, H; Sander, M; Schoenfeld, H; Spies, C; von Heymann, C; Ziemer, S | 1 |
| Amano, T; Hamaguchi, Y; Hayashi, Y; Ishii, H; Izawa, H; Matsubara, T; Miura, M; Murohara, T; Ogawa, Y; Torigoe, M; Yoshida, T | 1 |
| Horstkotte, D; Jaster, M; Knie, W; Pauschinger, M; Rauch, U; Schultheiss, HP; Spencker, S; Stellbaum, C; Willich, T | 1 |
| Huang, N; Pan, CJ; Shao, ZY; Tang, JJ; Wang, J | 1 |
| Alekseeva, IA; Dobrovol'skiĭ, AB; Liakishev, AA; Nasonov, EL; Naumov, VG; Parfenova, EV; Tkachuk, VA | 1 |
1 review(s) available for fibrinogen and Coronary Restenosis
| Article | Year |
|---|---|
[Fibrinogen and atherothrombosis: vulnerable plaque or vulnerable patient?].
Topics: Acute Disease; Angioplasty, Balloon, Coronary; Arteriosclerosis; Blood Component Removal; Coronary Restenosis; Female; Fibrinogen; Fibrinolytic Agents; Humans; Hypolipidemic Agents; Male; Meta-Analysis as Topic; Myocardial Infarction; Predictive Value of Tests; Primary Prevention; Prospective Studies; Risk Factors; Stents; Stroke; Syndrome; Thrombosis | 2003 |
1 trial(s) available for fibrinogen and Coronary Restenosis
| Article | Year |
|---|---|
-455G/A polymorphism and preprocedural plasma levels of fibrinogen show no association with the risk of clinical restenosis in patients with coronary stent placement.
Topics: Aged; Coronary Restenosis; Female; Fibrinogen; Follow-Up Studies; Humans; Male; Middle Aged; Myocardial Revascularization; Polymorphism, Single Nucleotide; Predictive Value of Tests; Regression Analysis; Risk; Stents | 2005 |
11 other study(ies) available for fibrinogen and Coronary Restenosis
| Article | Year |
|---|---|
The relationship between fibrinogen-to-albumin ratio and in-stent restenosis in patients with coronary artery disease undergoing drug-eluting stenting.
Topics: Coronary Angiography; Coronary Artery Disease; Coronary Occlusion; Coronary Restenosis; Coronary Vessels; Drug-Eluting Stents; Female; Fibrinogen; Humans; Male; Middle Aged; Percutaneous Coronary Intervention; Predictive Value of Tests; Prognosis; Retrospective Studies; Risk Adjustment; Serum Albumin | 2020 |
The effects of pharmacological PAI-1 inhibition on thrombus formation and neointima formation after arterial injury.
Topics: Angioplasty, Balloon, Coronary; Animals; Cell Proliferation; Coronary Restenosis; Coronary Vessels; Disease Models, Animal; Fibrinogen; Gene Expression Regulation; Hyperplasia; Male; Mice; Mice, Inbred C57BL; Plasminogen Activator Inhibitor 1; Rats; Rats, Sprague-Dawley; Thiazolidinediones; Thrombosis; Tunica Intima | 2008 |
Predictors of target lesion revascularization in patients undergoing lower extremity percutaneous interventions.
Topics: Aged; Angioplasty, Balloon, Coronary; Biomarkers; C-Reactive Protein; Cohort Studies; Complement C5a; Coronary Artery Disease; Coronary Restenosis; Extremities; Female; Fibrin Fibrinogen Degradation Products; Fibrinogen; Follow-Up Studies; Humans; Ischemia; Male; Middle Aged; Predictive Value of Tests; Prospective Studies; Registries; Regression Analysis; Risk Factors; Sex Factors | 2009 |
Synthetic peptide fragment (65-76) of monocyte chemotactic protein-1 (MCP-1) inhibits MCP-1 binding to heparin and possesses anti-inflammatory activity in stable angina patients after coronary stenting.
Topics: Acute-Phase Reaction; Aged; Angina Pectoris; Angioplasty; Anti-Inflammatory Agents; C-Reactive Protein; Chemokine CCL2; Coronary Angiography; Coronary Restenosis; Female; Fibrinogen; Heparin; Humans; Male; Middle Aged; Monocytes; Myocardial Ischemia; Peptide Fragments; Protein Binding; Protein Structure, Tertiary; Stents | 2011 |
Plasma fibrinogen levels and restenosis after primary percutaneous coronary intervention.
Topics: Aged; Angina, Stable; Cardiac Catheterization; Coronary Angiography; Coronary Restenosis; Female; Fibrinogen; Follow-Up Studies; Humans; Male; Middle Aged; Retrospective Studies | 2012 |
Predictive value of preprocedural fibrinogen concerning coronary stenting.
Topics: Aged; Analysis of Variance; Angioplasty, Balloon, Coronary; Biomarkers; Cohort Studies; Coronary Angiography; Coronary Restenosis; Coronary Stenosis; Female; Fibrinogen; Heart Function Tests; Humans; Male; Middle Aged; Postoperative Period; Predictive Value of Tests; Preoperative Care; Probability; Prognosis; Prospective Studies; Risk Assessment; Sensitivity and Specificity; Severity of Illness Index; Stents; Treatment Outcome; Vascular Patency | 2002 |
Clopidogrel-related refractory bleeding after coronary artery bypass graft surgery: a rationale for the use of coagulation factor concentrates?
Topics: Clopidogrel; Coronary Artery Bypass; Coronary Restenosis; Drug Administration Schedule; Factor VIIa; Factor XIII; Fibrinogen; Hemorrhage; Hemostasis, Surgical; Humans; Male; Middle Aged; Platelet Aggregation Inhibitors; Recombinant Proteins; Reoperation; Retreatment; Ticlopidine; Treatment Outcome | 2005 |
Impact of plasma aldosterone levels for prediction of in-stent restenosis.
Topics: Aged; Aldosterone; Angina Pectoris; Biomarkers; C-Reactive Protein; Cholesterol, LDL; Coronary Angiography; Coronary Restenosis; Female; Fibrinogen; Follow-Up Studies; Humans; Male; Natriuretic Peptide, Brain; Postoperative Complications; Prospective Studies; Regression Analysis; Renin; ROC Curve; Stents | 2006 |
The amount of fibrinogen-positive platelets predicts the occurrence of in-stent restenosis.
Topics: Adult; Aged; Angioplasty, Balloon, Coronary; Biomarkers; Blood Platelets; Coronary Restenosis; Female; Fibrinogen; Flow Cytometry; Follow-Up Studies; Humans; Male; Middle Aged; Myocardial Infarction; Predictive Value of Tests; Risk Factors; Stents; Thrombospondins; Ultrasonography, Interventional | 2008 |
Improved blood compatibility of rapamycin-eluting stent by incorporating curcumin.
Topics: Absorbable Implants; Adsorption; Angioplasty, Balloon, Coronary; Blood; Coated Materials, Biocompatible; Coronary Restenosis; Curcumin; Fibrinogen; Humans; In Vitro Techniques; Lactic Acid; Materials Testing; Microscopy, Electron, Scanning; Platelet Adhesiveness; Polyglycolic Acid; Polylactic Acid-Polyglycolic Acid Copolymer; Polymers; Sirolimus; Spectroscopy, Fourier Transform Infrared; Stents | 2007 |
[Acute phase proteins and recurrence of angina after effective coronary angioplasty].
Topics: Acute-Phase Proteins; Adult; Aged; Angina Pectoris; Angioplasty, Balloon, Coronary; Biomarkers; C-Reactive Protein; Coronary Restenosis; Factor Analysis, Statistical; Female; Fibrinogen; Humans; Male; Middle Aged; Plasminogen Activator Inhibitor 1; Predictive Value of Tests; Recurrence; Risk Factors | 2002 |